Q1 Earnings Forecast for STOK Issued By HC Wainwright

Stoke Therapeutics, Inc. (NASDAQ:STOK) – Research analysts at HC Wainwright issued their Q1 2025 earnings estimates for shares of Stoke Therapeutics in a report issued on Wednesday, March 19th. HC Wainwright analyst A. Fein anticipates that the company will post earnings per share of ($0.53) for the quarter. HC Wainwright currently has a “Buy” rating and a $47.00 target price on the stock. The consensus estimate for Stoke Therapeutics’ current full-year earnings is ($2.01) per share. HC Wainwright also issued estimates for Stoke Therapeutics’ Q2 2025 earnings at ($0.54) EPS.

Stoke Therapeutics (NASDAQ:STOK) last posted its earnings results on Monday, March 24th. The company reported ($0.18) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.56) by $0.38. Stoke Therapeutics had a negative return on equity of 54.45% and a negative net margin of 629.90%. The company had revenue of $22.61 million during the quarter, compared to analysts’ expectations of $4.20 million.

STOK has been the topic of a number of other research reports. Needham & Company LLC reaffirmed a “buy” rating and issued a $22.00 price target on shares of Stoke Therapeutics in a research report on Tuesday. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Stoke Therapeutics in a report on Tuesday, December 10th. Finally, Chardan Capital reaffirmed a “buy” rating and issued a $24.00 price objective on shares of Stoke Therapeutics in a report on Wednesday. One investment analyst has rated the stock with a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, Stoke Therapeutics currently has an average rating of “Buy” and an average target price of $23.00.

Stoke Therapeutics Trading Down 2.2 %

Shares of NASDAQ:STOK opened at $8.15 on Thursday. The company has a market capitalization of $431.68 million, a price-to-earnings ratio of -3.88 and a beta of 0.99. Stoke Therapeutics has a 12-month low of $5.93 and a 12-month high of $17.58. The business has a 50-day moving average price of $9.47 and a 200 day moving average price of $11.45.

Institutional Trading of Stoke Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the business. Bank of New York Mellon Corp increased its position in Stoke Therapeutics by 1.4% in the 4th quarter. Bank of New York Mellon Corp now owns 93,195 shares of the company’s stock worth $1,028,000 after purchasing an additional 1,330 shares during the last quarter. Graham Capital Management L.P. lifted its stake in shares of Stoke Therapeutics by 8.5% in the fourth quarter. Graham Capital Management L.P. now owns 18,634 shares of the company’s stock worth $206,000 after buying an additional 1,453 shares during the last quarter. Gilder Gagnon Howe & Co. LLC boosted its holdings in Stoke Therapeutics by 2.0% during the fourth quarter. Gilder Gagnon Howe & Co. LLC now owns 92,546 shares of the company’s stock valued at $1,021,000 after acquiring an additional 1,791 shares during the period. Price T Rowe Associates Inc. MD boosted its stake in Stoke Therapeutics by 6.3% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 37,455 shares of the company’s stock valued at $414,000 after purchasing an additional 2,215 shares during the period. Finally, Rhumbline Advisers boosted its position in shares of Stoke Therapeutics by 6.0% in the fourth quarter. Rhumbline Advisers now owns 49,374 shares of the company’s stock valued at $545,000 after acquiring an additional 2,787 shares during the period.

Insider Activity at Stoke Therapeutics

In other news, insider Barry Ticho sold 3,884 shares of the stock in a transaction that occurred on Tuesday, March 18th. The shares were sold at an average price of $8.67, for a total value of $33,674.28. Following the completion of the transaction, the insider now directly owns 63,962 shares in the company, valued at $554,550.54. This trade represents a 5.72 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Edward M. Md Kaye sold 10,382 shares of the company’s stock in a transaction dated Tuesday, March 18th. The shares were sold at an average price of $8.67, for a total transaction of $90,011.94. Following the completion of the sale, the director now directly owns 148,253 shares of the company’s stock, valued at $1,285,353.51. The trade was a 6.54 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 16,532 shares of company stock valued at $143,332 in the last quarter. Insiders own 11.30% of the company’s stock.

About Stoke Therapeutics

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.